For broader research context on nootropic compounds, including comparative stacks, cycling considerations, and interaction notes, see the Complete Nootropic Cheat Sheet.
What Is Adamax?
Adamax is a synthetic nootropic peptide analog developed in Russia at the same research institutions responsible for Semax and Selank. It belongs to the class of ACTH/MSH-derived peptides and is structurally related to Semax, sharing the core Pro-Gly-Pro tripeptide sequence that confers much of its neuroprotective activity.
Mechanism of Action
Like other melanocortin peptide analogs, Adamax interacts with melanocortin receptors and modulates BDNF expression in key brain regions including the hippocampus and prefrontal cortex. It also demonstrates anti-inflammatory properties in the CNS by reducing expression of pro-inflammatory cytokines in neural tissue.
Research Applications
Adamax has been studied for cognitive enhancement, neuroprotection against ischemic injury, anxiolytic effects, and stress resilience. Animal studies show improved performance on memory and learning tasks, reduced anxiety-like behavior, and protection against hippocampal damage in models of ischemia. It is typically administered intranasally like Semax, as this route maximizes CNS delivery while minimizing peripheral enzymatic degradation.
Quick Reference
Member reference tables summarize the compound's research parameters.
Research Indications
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Peptide Interactions
This member section summarizes reported compound interactions and evidence limitations.
Reported Research Time Points
This member section summarizes reported research time points.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Quality Indicators
Research Citations
- Adamax: A Novel Semax Derivative with Enhanced Nootropic Properties
Various Researchers, 2024-2025, Peptide Research Compilations - Adamax & P21: Two New Nootropic Peptides To Watch Closely
Campbell, J., 2024, Jay Campbell Research - The Regulatory Peptide Semax: Nootropic and Neuroprotective Effects (Parent Compound)
Ashmarin, I.P., et al., 1997, Russian Journal of Genetics - Peptide Semax Affects the Expression of Genes Related to Immune and Vascular Systems in Rat Brain Ischemia (Parent Compound)
Medvedeva, E.V., et al., 2014, BMC Genomics - Rapid Elevation of BDNF Expression Following Semax Administration (Parent Compound)
Shadrina, M.I., Dolotov, O.V., et al., 2010, Doklady Biochemistry and Biophysics